Software AG

  • WKN: A2GS40
  • ISIN: DE000A2GS401
  • Land: Germany

Nachricht vom 11.04.2019 | 21:53

SOFTWARE AG PUBLISHES PRELIMINARY Q1 2019 FINANCIAL RESULTS AND RAISES 2019 OUTLOOK FOR ADABAS & NATURAL BUSINESS LINE

Software AG / Key word(s): Change in Forecast/Preliminary Results
SOFTWARE AG PUBLISHES PRELIMINARY Q1 2019 FINANCIAL RESULTS AND RAISES 2019 OUTLOOK FOR ADABAS & NATURAL BUSINESS LINE

11-Apr-2019 / 21:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc Disclosure (Inside Information according to article 17 MAR)

SOFTWARE AG PUBLISHES PRELIMINARY Q1 2019 FINANCIAL RESULTS AND RAISES 2019 OUTLOOK FOR ADABAS & NATURAL BUSINESS LINE

- Total revenue at EUR 201.4 million up by 8% year-on-year

- Total product revenue at EUR 154.5 million up by 10% year-on-year

- Total license revenue at EUR 42.6 million up by 25% year-on-year

- A&N business at EUR 54.7 million up by 22% year-on-year

- DBP business (excluding IoT/Cloud) at EUR 90.5 million up by 1% year-on-year

- Cloud & IoT business EUR 9.5 million up by 49% year-on-year

- EBIT at EUR 42.2 million in line with prior year level

- EBITA (non-IFRS) margin at 25.6%

- A&N outlook corridor raised to -3% to +3% (previously -5 to 0%) revenue growth at constant currency

- All other 2019 outlook numbers re-confirmed

- Analyst conference call to be held on April 12th, 2019 at 09:00 CEST

Today, the Management Board of Software AG (MDAX, ISIN DE000A2GS401 / SOW) pre-announced its financial figures (IFRS, preliminary) for the first quarter of 2019. According to an initial consolidation of the results, the company showed higher than expected license revenue in the A&N business line driven by the capacity extensions of major deals. Due to a few deal slippages from Q1 to Q2, the revenue of DBP excluding Cloud & IoT increased only by 1% compared to the previous year's level. Software AG's Cloud & IoT revenue increase of 49% in Q1 does not yet fully reflect the company's dynamic growth expectation for the full year (75% to 125%). The slower start in the new year in DBP and Cloud & IoT was impacted by the reorganization of the salesforce in North America and a late global sales kick-off which led to a slower execution in Q1 versus the previous year. Including professional services of EUR 46.7 million (previous year: EUR 46.1 million), the company's total revenue in the first quarter increased by 8 percent reaching EUR 201.4 million. Based on an initial consolidation of the results, the expected EBIT will be EUR 42.2 million, and in line with the prior year's level. Reflecting the HELIX investments, the Group's EBITA (non-IFRS) margin will be 25.6% (previous year 27.4%). Based on the current business development and the pipeline at the end of Q1 2019, Software AG's Management Board raised its 2019 outlook for A&N to -3% to +3% (previously -5% to 0%) revenue growth at constant currency. The 2019 outlook for DBP (+3% to +7% revenue growth at constant currency), Cloud & IoT (+75% to +125% revenue growth at constant currency) and EBITA margin (non-IFRS) (28% to 30%) remain unchanged.

An analyst & media call will be held on Friday, 12 April 2019 at 09:00 CEST.

The full Q1 financial figures will be published on April 18th, 2019.

Darmstadt, April 11, 2019

Software AG

The Management Board




Contact:
Person making the notification:
Frederic Freichel
Manager Investor Relations

Email: frederic.freichel@softwareag.com
Tel: +49 6151 92 1106

11-Apr-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021